DRAFT 

REPORT TO THE ADVISORY BOARD 

ON RADIATION AND WORKER HEALTH

National Institute for Occupational Safety and Health 

COMPARISON OF SC&A’S BLIND DOSE RECONSTRUCTION 

TO NIOSH’S DOSE RECONSTRUCTION OF CASE #[REDACT] 

FROM THE BROOKHAVEN NATIONAL LABORATORY 

Contract No. 211-2014-58081 

SCA-TR-DRC2015-CN[Redact]

Prepared by 

Ron Buchanan, PhD, CHP 

S. Cohen & Associates 

1608 Spring Hill Road, Suite 400 

Vienna, Virginia 22182 

March 2015 

Disclaimer

This document is made available in accordance with the unanimous desire of the Advisory Board on 

Radiation and Worker Health (ABRWH) to maintain all possible openness in its deliberations. However, 

the ABRWH and its contractor, SC&A, caution the reader that at the time of its release, this report is predecisional and has not been reviewed by the Board for factual accuracy or applicability within the 

requirements of 42 CFR 82. This implies that once reviewed by the ABRWH, the Board’s position may 

differ from the report’s conclusions. Thus, the reader should be cautioned that this report is for 

information only and that premature interpretations regarding its conclusions are unwarranted.
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

2 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

S. Cohen & Associates:

Technical Support for the Advisory Board on

Radiation & Worker Health Review of

NIOSH Dose Reconstruction Program

Document No. 

SCA-TR-DRC2015-CN[Redact]

Effective Date: 

Draft – March 30, 2015

Comparison of SC&A’s Blind Dose 

Reconstruction to NIOSH’s Dose 

Reconstruction of Case #[Redact] from the 

Brookhaven National Laboratory

Page 2 of 20

Task Manager:

_______________________ Date: ___________

Rose Gogliotti

Supersedes:

N/A

Project Manager:

_______________________ Date: ___________

John Stiver, MS, CHP

Reviewer:

 Rose Gogliotti

 Kathleen Behling

 Doug Farver

 John Stiver

Record of Revisions

Revision 

Number Effective Date Description of Revision

0 (Draft) 03/30/2015 Initial issued.
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

3 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

TABLE OF CONTENTS 

Abbreviations and Acronyms ..........................................................................................................5

1.0 Relevant Background Information .......................................................................................7

2.0 Comparison of Methodology/Doses used by SC&A and NIOSH for Case 

#[REDACT] .....................................................................................................................................9

2.1 Occupational External Dose Calculations .............................................................11

2.1.1 Recorded/Unmonitored Photon and Neutron Doses ..................................11

2.1.2 Missed Photon and Neutron Doses ............................................................12

2.1.3 Onsite Ambient Doses ...............................................................................14

2.1.4 Occupational Medical Doses .....................................................................14

2.2 Occupational Internal Doses ..................................................................................15

2.2.1 Internal Environmental Dose .....................................................................16

3.0 Summary Conclusions .......................................................................................................17

4.0 References ..........................................................................................................................19

Addendum A: SC&A’s Blind Dose Reconstruction Report of Case #[REDACT] ......................20
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

4 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

LIST OF TABLES 

Table 1-1. Comparison of SC&A’s Blind Dose Reconstruction to 

NIOSH’s Dose Reconstruction for Case #[Redact] ......................................................8

Table 2-1. Comparison of External Dose Data and Assumptions 

Used by SC&A and NIOSH .......................................................................................10

Table 2-2. Comparison of Internal Dose Data and Assumptions 

Used by SC&A and NIOSH .......................................................................................11

Table 2-3. Comparison of Recorded/Unmonitored Photon and Neutron Doses ..........................12

Table 2-4. Comparison of Missed Photon and Neutron Doses .....................................................14

Table 2-5. Comparison of Internal Environmental Doses ............................................................16

Table 3-1. Comparison of SC&A’s and NIOSH’s Total External and 

Internal Dose Estimates for the Nasal Cavity .............................................................17
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

5 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

ABBREVIATIONS AND ACRONYMS 

Advisory Board Advisory Board on Radiation and Worker Health 

BGRR Brookhaven Graphite Research Reactor 

BNL Brookhaven National Laboratory 

CADW Chronic Annual Dose Workbook 

CATI Computer-Assisted Telephone Interview 

CW coworker 

DCF dose conversion factor

DOE (U.S.) Department of Energy 

DOL (U.S.) Department of Labor 

DR dose reconstruction 

EE energy employee 

GSD geometric standard deviation

HFBR High Flux Beam Reactor 

HHS (U.S. Department of) Health and Human Services 

ICD International Classification of Diseases 

ICRP International Commission on Radiological Protection 

IREP Interactive RadioEpidemiological Program 

keV kilo electron volt; 1,000 electron volts 

LAT lateral 

LOD limit of detection

MeV Million electron volts 

NIOSH National Institute for Occupational Safety and Health 

NM not monitored 

NTA Eastman Kodak Nuclear Track Film Type A 

PA posterior-anterior 

PFG photofluorography

POC probability of causation 

rem Roentgen equivalent man 

SC&A S. Cohen and Associates (SC&A, Inc.) 

SEC Special Exposure Cohort 

SID Source to image distance 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

6 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

TBD technical basis document 

y year
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

7 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

1.0 RELEVANT BACKGROUND INFORMATION 

Under Contract No. 211-2014-58081, SC&A was tasked by the Advisory Board on Radiation 

and Worker Health (Advisory Board) to perform six blind dose reconstructions (DRs) at the July 

2014, DR Subcommittee meeting. SC&A was provided all of the Department of Energy (DOE) 

dosimetry records; the Department of Labor (DOL) correspondence, forms, and medical records; 

and the Computer-Assisted Telephone Interview (CATI) Reports that were made available to the 

National Institute for Occupational Safety and Health (NIOSH) for constructing doses in behalf 

of these cases. SC&A used an independent approach to reconstruct occupational external and 

internal doses for the cases using the available dosimetry records and current guidance from 

NIOSH, including the spreadsheets and other tools developed by NIOSH to calculate the doses. 

On February 12, 2015, SC&A submitted to the Advisory Board and NIOSH a memorandum 

containing the summary results of our blind DR in behalf of Case #[Redact] (SC&A 2015a). 

The complete DR report entitled, SC&A’s Dose Reconstruction of Case #[Redact] from the 

Brookhaven National Laboratory (SC&A 2015b), which provides the assumptions and 

methodologies used to derived occupational radiation doses and the resultant probability of 

causation (POC), is included herein as Addendum A. In this report, SC&A presents a 

comparison between NIOSH’s and SC&A’s DR methodologies, doses, and resultant POC values 

for Case #[Redact]. Table 1-1 summarizes the external and internal occupational doses 

calculated by SC&A and the NIOSH-assigned doses for the nasal cavity cancer diagnosed in 

behalf of Case #[Redact]. A detailed comparison of the two methodologies used to calculate 

doses in behalf of this case is presented in Section 2. Section 3 of this report provides Summary 

Conclusions. 

It should be noted that, where appropriate, an explanation is provided regarding the differences 

in doses and why they occurred; however, SC&A does not make any value judgments regarding 

which among them may be the more preferred approach. It is our position that further 

discussions are best addressed by the DR Subcommittee. 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

8 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

Table 1-1. Comparison of SC&A’s Blind Dose Reconstruction to

NIOSH’s Dose Reconstruction for Case #[Redact] 

SC&A Nasal Cavity 

Doses (rem)

NIOSH Nasal Cavity 

Doses (rem)

External Dose:

 ▪ Recorded/Unmonitored Dose

 - Photons 30–250 keV 5.664 5.350

 - Photons >250 keV 11.469 11.421

 - Neutrons 1.802 1.386

 ▪ Missed Dose

 - Photons 30–250 keV 1.550 1.338

 - Photons >250 keV 3.138 3.165

 - Neutrons 11.917 20.467

 ▪ Occupational Medical Dose

 - Photons 30–250 keV 0.157 0.478

Internal Dose:

 <15 keV electrons 0.161 0.159

 >15 keV electrons 102.385 101.625

 <30 keV Photons 0.096 0.094

 >250 keV Photons 4.680 4.571

 Alpha 0.971 0.944

Total Cancer Dose 143.990 150.998

POC 51.05% 52.54%
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

9 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

2.0 COMPARISON OF METHODOLOGY/DOSES USED BY SC&A AND 

NIOSH FOR CASE #[REDACT] 

Case #[Redact] represents an energy employee (EE) who worked at the Brookhaven National 

Laboratory (BNL) from [redact] through [redact]. Based on DOL records and the CATI, the 

EE worked as a [redact] and [redact] at the BNL. The EE first worked at the Brookhaven 

Graphite Research Reactor (BGRR) and then the High Flux Beam Reactor (HFBR). The EE was 

monitored for external photon exposure during most of the employment period at BNL. The EE 

was diagnosed with nasal cavity cancer (sinonasal melanomas of the [redact] nasal cavity, ICD9 Code 160.0) on [redact].

This was a partial DR, because not all internal doses could be assigned, as per the BNL Special 

Exposure Cohort (SEC). According to ORAUT-TKBS-0048, page 12, the Secretary of the U.S. 

Department of Health and Human Services (HHS) has designated BNL employees as an addition 

to the SEC. Based on the findings and recommendations of NIOSH and the Advisory Board on 

Radiation and Worker Health, the Secretary of the HHS has concurred with the finding that 

NIOSH does not have access to sufficient personnel or area monitoring data, or sufficient source 

or source term information, about BNL operations to bound potential internal exposures for the 

period from January 1, 1947, through December 31, 1993 (other than tritium after December 31, 

1964). 

The EE was employed at BNL during the SEC period; however, since nasal cavity cancer is 

considered a non-presumptive cancer, it was not covered under the SEC class. Therefore, a DR 

was required. 

For calculating radiation doses from employment at BNL, both DR methods primarily relied on 

guidance in the BNL Technical Basis Document (TBD) (ORAUT-TKBS-0048). Using the 

guidance provided in this document, along with the employee’s dosimetry records, SC&A 

employed a best-estimate approach for calculating annual organ external and internal doses, 

while NIOSH employed a best-estimate approach for calculating annual organ external doses 

and a minimizing approach for calculating annual organ internal doses. This resulted in both 

SC&A and NIOSH deriving a POC of >50%. 

A summary of the documents, assumptions, and dose parameters used by each DR method is 

provided in Tables 2-1 and 2-2: 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

10 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

Table 2-1. Comparison of External Dose Data and Assumptions 

Used by SC&A and NIOSH 

Parameters SC&A NIOSH

External Recorded or Unmonitored Dose:

Records/Guidance Documents DOE records, BNL TBD, and 

ORAUT-OTIB-0005.

DOE records, BNL TBD, ORAUT-OTIB0005, and the BNL Dose Calculation 

Workbook 2.04.

Work Locations BGRR & HFBR BGRR & HFBR

Energy Range

25% 30–250 keV 

75% >250 keV

100% 0.1–2 MeV neutrons

25% 30–250 keV 

75% >250 keV

100% 0.1–2 MeV neutrons

Exposure Organ DCFs

30–250 keV DCF = 1.440

>250 keV DCF = 0.972

0.1–2 MeV neutrons DCF = 1.086

Monte Carlo generated centered on:

30–250 keV DCF = 1.440

>250 keV DCF = 0.972

0.1–2 MeV neutrons DCF = 1.086

ICRP-60 Correction F. 1.91 1.91

Neutron Fading F. 1.81 1.81

Dose Distribution Normal; 30% uncertainty. Normal; 30% uncertainty.

External Missed Dose:

Records/Guidance Documents DOE records, OCAS-IG-001, 

PROC-0006, and BNL TBD.

DOE records, OCAS-IG-001, PROC0006, BNL TBD and the BNL Dose 

Calculation Workbook 2.04.

No. of zeros 287 photons, 383 neutrons 238 photons, 385.5 neutrons

LOD Value 0.030 rem photon & neutron 0.030 rem photon & neutron

Energy Range

25% 30–250 keV 

75% >250 keV

100% 0.1–2 MeV neutrons

25% 30–250 keV 

75% >250 keV

100% 0.1–2 MeV neutrons

Exposure Organ DCFs

30–250 keV DCF = 1.440

>250 keV DCF = 0.972

0.1–2 MeV neutrons DCF = 1.086

Monte Carlo generated centered on:

30–250 keV DCF = 1.440

>250 keV DCF = 0.972

0.1–2 MeV neutrons DCF = 1.086

ICRP-60 Correction F. 1.91 1.91

Neutron Fading F. None 1.81

Dose Distribution Lognormal with GSD = 1.52 Lognormal with GSD centered around 

1.52

Shallow Dose:

NA NA

Coworker Dose:

Records/Guidance Documents BNL TBD, Table 6-2 NA

Energy Range 25% 30–250 keV 

75% >250 keV NA

Exposure Organ DCFs 30–250 keV DCF = 1.440

>250 keV DCF = 0.972 NA

Dose Distribution Normal; 30% uncertainty. NA

Onsite External Ambient Dose:

NA NA

Occupational Medical Dose:

Guidance Documents BNL TBD, ORAUT-OTIB-0006 BNL TBD

Frequency 22 documented x-ray exams 22 documented x-ray exams

Dose Distribution Normal; GSD = 30%. Normal; GSD = 30%.

NA = not applicable or not analyzed. 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

11 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

Table 2-2. Comparison of Internal Dose Data and Assumptions 

Used by SC&A and NIOSH 

Parameters SC&A NIOSH

Bioassay Internal:

Records/Guidance Documents Bioassay records not available Bioassay records not available

Environmental Internal:

Records/Guidance Documents BNL TBD, CADW BNL TBD, CADW

Dose Determination Approach Best-estimate methodology Minimizing methodology

Solubility Type Site default that max. dose Site default that max. dose

Dose Distribution Lognormal, GSD of 3.000 Lognormal, GSD of 3.000

2.1 OCCUPATIONAL EXTERNAL DOSE CALCULATIONS 

2.1.1 Recorded/Unmonitored Photon and Neutron Doses 

The DOE records show that the EE was monitored at BNL during each year from [redact]

through [redact], with some quarterly badge exchanges recorded as not monitored (NM). The 

records indicate that the EE was not monitored (NM recorded) for two quarters during the year 

[redact], and 14 quarters during the period [redact]–[redact]. Because the BGRR did not 

operate until [redact] (ORAUT-TKBS-0048 page 26), neither SC&A nor NIOSH assigned doses 

for the two quarters the EE was not monitored during [redact]. 

[Redact]–[redact] NM Quarters

The quarterly total recorded doses, and zero values, for photon, neutron, and shallow doses in the 

EE’s DOE files were very well organized and legible (shallow dose is not applicable to the nasal 

cavity). However, both SC&A and NIOSH found that there was one discrepancy in the DOE 

radiation report for the 2nd quarter of [redact]. This report cited a Lifetime Total dose that was 

0.440 rem greater than the total dose calculated when summing up the quarterly values through 

the 2nd quarter of [redact] (14.590 rem vs. 14.150 rem). 

SC&A’s Method for Assigning Dose during NM Periods 

The additional 0.440 rem of recorded exposure in the [redact] summary sheet could have 

occurred any time in the 14 NM periods between [redact] and [redact], and may not have been 

entered into the quarterly sums, but carried in the Lifetime Total dose records. Therefore, to be 

claimant favorable, 0.220 rem was assigned to the first potentially missed monthly exchange in 

[redact], and the remaining 0.220 rem assigned to the second potentially missed monthly 

exchange in [redact], which occurred during the 3rd quarter. The total 0.440 rem was not 

assigned during one monthly exchange, because that would exceed the 5-rem per year dose limit 

applicable at that time; i.e., 5.000 rem/y × (1/12 months/y) = 0.417 rem/month maximum. For 

all the other potentially missed monthly exchanges during the period [redact]–[redact], which 

had the NM notation in the records (as per ORAUT-TKBS-0048, page 82, recommendations for 

lost or destroyed badges), a monthly photon prorated coworker (CW) dose was derived from the 

annual dose values as recommended in ORAUT-TKBS-0048, Table 6-2, page 84. This 

amounted to approximately 0.026 rem/month. SC&A did not assign CW neutron doses during 

unmonitored periods, because the POC was >50% without assigning CW neutron dose. 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

12 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

NIOSH’s Method for Assigning Dose during NM Periods 

NIOSH distributed the additional photon dose (0.440 rem) evenly over the 14 quarters when NM 

was recorded, starting with the third quarter of 1950; NIOSH did not assign CW dose. NIOSH 

did not assign additional neutron doses, because the sum of the quarterly neutron doses was 

slightly greater than the reported total, indicating no neutron dose had been missed in the 

quarterly records. 

Comparison of SC&A’s and NIOSH’s Methods and Doses for Recorded Photons and Neutrons 

Both DR methods assumed the EE worked primarily in reactor areas. Therefore, both SC&A 

and NIOSH used the DR parameters as recommended in ORAUT-TKBS-0048, which consisted 

of an energy range of 25% 30–250 keV photons, 75% >250 keV photons (Table 6-3, page 86); 

and 100 keV–2 MeV neutrons with a neutron ICRP-60 (ICRP 1991) correction factor of 1.91 

(Table 6-5, page 87) and a Nuclear Track Film Type A (NTA) dosimeter fading correction factor 

of 1.81 (page 91). Exposure (as opposed to deep dose) conversion factors (DCFs) were used, as 

per ORAUT-TKBS-0048, page 90. The thyroid was used as the surrogate organ for the nasal 

cavity (ORAUT-OTIB-0005, page 15) because of it being in approximately the same physical 

location. A limit of detection (LOD) value of 0.030 rem for both photons and neutrons with a 

monthly badge exchange was assumed (ORAUT-TKBS-0048, Table 6-1, page 82). SC&A used 

the mode DCF values listed in OCAS-IG-001; however, NIOSH used Monte Carlo-generated 

DCFs based on the triangular distribution of DCF values listed in OCAS-IG-001.

Using the EE’s dosimetry records and above-cited parameters, SC&A and NIOSH assigned 

photon and neutron recorded doses as shown in Table 2-3. The slightly larger photon doses 

assigned by SC&A reflect the use of CW data for NM periods, as opposed to NIOSH’s method 

of spreading the unaccounted for 0.440 rem dose over the 14 NM periods. NIOSH’s lower 

neutron dose resulted from the use of Monte Carlo DCFs, as opposed to the mode values in 

OCAS-IG-001, and not including the relatively small recorded neutron doses >LOD/2 for the 

years [redact], [redact], and [redact] in the measured neutron dose assignments. 

Table 2-3. Comparison of Recorded/Unmonitored Photon and Neutron Doses 

SC&A (rem) NIOSH (rem)

Total Recorded/Unmonitored Photon Dose 17.133 16.771

Total Recorded Neutron Dose 1.802 1.386

Both DR methods entered doses into the Interactive RadioEpidemiological Program (IREP) as a 

normal distribution with 30% uncertainty. 

2.1.2 Missed Photon and Neutron Doses 

Missed photon and neutron doses were assigned by both SC&A and NIOSH. 

SC&A’s Missed Photon and Neutron Doses 

SC&A analyzed the number of actual zeros and potential zeros based on a monthly badge 

exchange cycle using the guidance in OCAS-IG-001 (page 16), ORAUT-PROC-0006, and a 

reasonable approach to arrive at a total of 287 zeros (or <LOD/2 values) for photons, and 

383 zeros (or <LOD/2 values) for neutrons. SC&A used the annual number of zeros, the LOD/2 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

13 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

value, the DR parameters listed above, and the applicable DCF to determine the annual missed 

photon and neutron doses. SC&A did not apply the neutron film fading factor of 1.81 to missed 

neutron dose (as was applied to recorded neutron dose), because ORAUT-TKBS-0048, page 91, 

states: 

For the period from site startup through 1984, a fading correction factor of 18% 

per week provides a reasonable overestimate of fading for NTA film dosimeters 

on an annual basis. For a monthly wear period with 1 week for reading of the 

dosimeter, an average time for fading would be 3 weeks. This corresponds to a 

loss of about 55% of the tracks. The recorded neutron doses should be corrected 

by applying a multiplication factor of 1.81 (inverse of 55%). [Emphasis added.] 

Therefore, SC&A interprets this to mean that the NTS film fading factor should only be applied 

to recorded neutron dose, and not to missed neutron dose. 

SC&A assigned a total missed photon dose of 4.688 rem and a total missed neutron dose of 

11.917 rem. 

NIOSH’s Missed Photon and Neutron Doses 

As stated in the DR Report, NIOSH calculated missed dose as described below: 

Based on information provided in the dosimetry records, the total number of 

dosimeter cycles assigned was 238 for photons and 385.5 for neutrons. The 

number of zero badge readings was based upon the reported zero readings plus 

the readings that were less than half the dosimeter’s limit of detection [OCAS-IG001 and ORAUT-TKBS-0048]. The dosimetry records prior to 1985 were 

available only as quarterly summaries. For this period, the number of zero badge 

readings was evaluated as a best estimate based on reported annual doses, dose 

limits, and the limit of detection [ORAUT-PROC-0006]. Missed dose was 

assigned based on the dosimeter’s limit of detection [OCAS-IG-001 and ORAUTTKBS-0048]. [Emphasis added.]

NIOSH used the annual number of zeros, the LOD/2 value, the DR parameters listed above, 

Monte Carlo-generated DCFs, and the 1.81 neutron film fading factor to determine the annual 

missed photon and neutron missed doses. NIOSH assigned a total missed photon dose of 

4.503 rem, and a total missed neutron dose of 20.467 rem. 

Comparison of SC&A’s and NIOSH’s Methods and Doses for Missed Photons and Neutrons

Using the EE’s dosimetry records and above-cited parameters, SC&A and NIOSH assigned 

missed photon and neutron doses as shown in Table 2-4. SC&A used the actual counting of 

zeros and potentially missed badge cycles to determine missed dose, whereas NIOSH used a 

program that determines the best-estimate number of zeros; therefore, while similar, the number 

of zeros do not match exactly. 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

14 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

Comparison of Missed Photon Dose 

The slightly larger missed photon dose assigned by SC&A was due to the fact that SC&A 

derived a greater number of zeros for photons; i.e., 287 vs. 238. SC&A investigated the missed 

photon doses derived by SC&A compared to NIOSH and by back calculations found that the 

Monte Carlo DCFs used by NIOSH were generally larger than the OCAS-IG-001 DCF values 

used by SC&A; this decreased the magnitude of the difference in assigned missed photon dose 

that would have otherwise occurred considering the difference in the number of zeros used. 

Comparison of Missed Neutron Dose 

The number of missed neutron doses used in this case was similar (SC&A used 383 and NIOSH 

used 385.5). The larger missed neutron dose assigned by NIOSH was due to fact that NIOSH 

applied the NTA film fading factor to missed neutron doses, while SC&A did not apply this 

correction factor based on above-cited guidance in ORAUT-TKBS-0048. 

Table 2-4. Comparison of Missed Photon and Neutron Doses 

SC&A (rem) NIOSH (rem)

Total Missed Photon Dose 4.688 4.503

Total Missed Neutron Dose 11.917 20.467

Both DR methods entered missed photon and neutron doses into IREP as a lognormal 

distribution with uncertainty centered on 1.520. 

2.1.3 Onsite Ambient Doses 

As per ORAUT-TKBS-0048, Section 4.2.2, page 59, external ambient dose should not be 

applied when the EE is assigned recorded (and/or CW) dose. Therefore, neither SC&A nor 

NIOSH assigned external ambient dose in this case, since the EE was assigned recorded and/or 

CW doses for all years of employment. 

2.1.4 Occupational Medical Doses 

Both DR methods: 

 Calculated an occupational medical dose from diagnostic x-ray procedures required as a 

condition of employment 

 Used the number and type of x-ray exams as provided in the EE’s DOE files 

 Used the thyroid or eye/brain as the surrogate organ for the nasal cavity for all posterioranterior (PA) and lateral (LAT) view exposures (the doses were identical for the thyroid 

and eye/brain for all PA and LAT views used in this case, as per ORAUT-TKBS-0048, 

Table 3-3, page 51) 

 Assigned LAT view doses for x-ray exams performed after [redact], as per ORAUTTKBS-0048, Table 3-1, page 46

 Used the recommended doses for PA, LAT, and photofluorography (PFG) exams for the 

thyroid or eye/brain (as a function of time) from ORAUT-TKBS-0048, Table 3-3, page 

51
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

15 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

 Assigned doses for 21 PA view, 3 LAT views, and 1 PFG x-ray exams. 

Comparison of Medical X-ray Assigned Doses 

Both SC&A and NIOSH assigned a total dose of 0.061 rem for the 21 PA view, and 0.024 rem 

from the 3 LAT view x-ray exams. However, for the [redact] PFG x-ray exam, NIOSH used the 

thyroid as the surrogate organ and assigned a dose of 0.394 rem, whereas SC&A assigned a dose 

of 0.073 rem using the eye/brain as the surrogate organ according to the recommendation on 

page 16 of ORAUT-OTIB-0006: 

The thyroid DCF is usually selected as the substitute to determine the dose to the 

eye/brain. However, one important exception to this generality is made for 

determining eye/brain dose from photofluorography (PFG) examinations of the 

chest. Because of the shorter SID used in PFG (40 in.) compared with 

radiographic chests (72 in.), the thyroid is most likely to be in the primary beam 

for PFG, while the eye/brain is most likely to be outside the primary beam of 

PFG. A better choice of a substitute DCF for the dose to the eye/brain for PFG is 

then one where the thyroid (as a substitute for the eye/brain) is just outside the 

primary beam. [Emphasis added.] 

The wording of the latter part (underlined) of the last sentence in this statement is not clear; 

however, SC&A interpreted it to mean that for PFG exams, an organ outside the primary beam is 

to be used instead of the thyroid (which may be in the primary beam) for cancers located at, or 

near, the eye/brain. Since the nasal cavity is located near the eye/brain, SC&A used the 

eye/brain dose cited in Table 3-3 of ORAUT-TKBS-0048 for the nasal cavity in this case. 

Table 2-5 shows a comparison of the occupational medical doses calculated by the two DR 

methods. The resulting total doses were identical for the PA and LAT views, but the PFG exam 

doses differed, as described above. 

Table 2-5. Comparison of Occupational Medical Doses 

View SC&A (rem) NIOSH (rem)

PA 0.061 0.061

LAT 0.024 0.024

PFG 0.073 0.394

Total: 0.157 0.478

Both methods entered annual doses into IREP as a normal distribution with an uncertainty of 

30%.

2.2 OCCUPATIONAL INTERNAL DOSES 

There were no recorded bioassay results for this EE in the DOE records. There was a request for 

a urine sample for plutonium analysis in [redact] and a whole-body count in [redact]; however, 

no results were recorded/available. According to the information provided in the site profile for 

BNL (ORAUT-TKBS-0048, page 12) and the SEC class definitions, internal radiation doses at 

the BNL from [redact], through [redact], cannot be reconstructed because the data necessary to 

estimate doses during this time period cannot be readily retrieved. Therefore, because no 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

16 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

bioassay data are available for the EE, no estimation techniques can be employed to derive 

internal dose, except for internal dose from the intake of ambient air activity. 

2.2.1 Internal Environmental Dose 

Both SC&A and NIOSH used the BNL site default radionuclides and associated intakes (as 

provided in Table 4-2 of ORAUT-TKBS-0048) for the years of employment in the Chronic 

Annual Dose Workbook (CADW) to derive the annual doses to the nasal cavity. 

SC&A’s Best-Estimate Method 

SC&A used the best-estimate method by assigning environmental intakes for the full years for 

[redact]–[redact] (employment termination date of [redact]) and deriving the annual dose 

through the year the cancer was diagnosed ([redact]).

NIOSH’s Minimizing Method 

NIOSH used a minimizing method by assigning environmental intakes for the full years for 

[redact]–[redact] (i.e., NIOSH did not assign intakes for the employment termination year of 

[redact]), which resulted in an approximately 1/36 decrease in intake and dose. In addition, 

NIOSH did not assign dose for the year the cancer was diagnosed ([redact]).

Table 2-6 shows a comparison of the internal doses calculated by the two DR methods. 

 

Table 2-5. Comparison of Internal Environmental Doses 

SC&A (rem) NISOH (rem)

<15 keV electrons 0.161 0.159

>15 keV electrons 102.385 101.625

Gamma <30 keV 0.096 0.094

Gamma 30–250 keV NA NA

Gamma >250 keV 4.680 4.571

Alpha 0.971 0.944

Total: 108.293 107.393

NA = not applicable or <0.001 rem. 

Both methods entered annual doses into IREP as a lognormal distribution with geometric 

standard deviation (GSD) of 3.000. 

Comparison of Internal Environmental Dose Methods and Results 

SC&A and NIOSH arrived at similar internal dose results. NIOSH’s assigned dose values were 

slightly less than SC&A’s, since NIOSH used a minimizing method as opposed to the bestestimate method used by SC&A. 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

17 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

3.0 SUMMARY CONCLUSIONS 

Total external and internal doses and resultant POCs calculated by SC&A and NIOSH in behalf 

of Case #[Redact] are presented in Table 3-1 for comparison. 

Table 3-1. Comparison of SC&A’s and NIOSH’s Total External and 

Internal Dose Estimates for the Nasal Cavity 

SC&A (rem) NIOSH (rem)

External Doses: 35.697 43.605

Internal Doses: 108.293 107.393

Total Dose: 143.990 150.998

POC: 51.05% 52.54%

As shown in Table 3-1, SC&A’s and NIOSH’s dose estimates and resulting POCs are in close 

agreement. The primary difference in assigned external dose was due to NIOSH applying an

NTA film fading factor to both recorded and missed neutrons dose, whereas SC&A only applied 

an NTA film fading factor to recorded neutron dose. 

A more detailed discussion of variables that contributed to key differences in dose assignments is 

presented below. 

 Dose Reconstruction Methodology 

– SC&A employed a best-estimate approach to DR throughout. 

– NIOSH employed a best-estimate approach to external doses, and a minimizing 

approach to internal DR.

 Dose Conversion Factors 

– SC&A applied the mode DCF values as recommended in OCAS-IG-001.

– NIOSH applied Monte Carlo-generated DCFs using OCAS-IG-001 data. 

– This difference in methodology resulted in slight differences in the assignment of 

recorded and missed photon and neutron doses. 

 Assignment of Unmonitored Dose

– SC&A assigned unmonitored photon dose based on 50th percentile CW data for 

periods where the records showed the EE was not monitored (NM), after assigning 

the unaccounted recorded dose of 0.440 rem to the first two NM periods. 

– NIOSH prorated the 0.440 rem of unaccounted recorded dose over all the 14 NM 

periods and did not use CW data. 

– This difference in methodology resulted in SC&A deriving slightly higher doses for 

unmonitored periods than NIOSH. 
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

18 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

 Assignment of Missed External Dose 

– SC&A assigned missed photon and neutron doses based on the actual and projected 

number of zeros and <LOD/2 values, identified in the EE’s DOE records. 

– NIOSH assigned missed photon and neutron doses based on best-estimate 

methodology. 

– This difference in methodology resulted in SC&A deriving slightly greater missed 

doses than NIOSH assigned. 

 Assignment of Neutron Dose

– SC&A applied the NTA film fading factor of 1.81 only to the recorded neutron dose, 

as per SC&A’s interpretation of the BNL TBD. 

– NIOSH applied the NTA film fading factor of 1.81 to both the recorded and missed 

neutron doses. 

– This difference in methodology resulted in NIOSH assigning a larger (by a factor of 

approximately 1.8) missed neutron dose as compared to SC&A. 

 Assignment of Onsite Ambient Dose 

– Neither SC&A nor NIOSH assigned onsite external ambient dose, because the EE 

was assigned recorded or unmonitored doses for the entire employment period. 

 Assignment of Occupational Medical X-ray Dose 

– To derive the x-ray doses, SC&A used the number of x-ray exams recorded in the 

DOE files and the dose values recommended in the BNL TBD, using the thyroid as 

the surrogate organ for the nasal cavity for PA and LAT views, and the eye/brain as 

the surrogate organ for the PFG exam. 

– To derive the x-ray doses, NIOSH used the number of x-ray exams recorded in the 

DOE files and the dose values recommended in the BNL TBD, using the thyroid as 

the surrogate organ for the nasal cavity for PA and LAT views, and also the thyroid 

as the surrogate organ for the PFG exam. 

– This difference methodology resulted in NIOSH assigning a larger PFG x-ray dose 

than that derived by SC&A.

 Assignment of Internal Dose 

– SC&A used the best-estimate approach to assign environmental intakes/doses. 

– NIOSH used a minimizing approach to assign environmental intakes/doses. 

– This difference in methodology resulted in NIOSH assigning a slightly less total 

internal dose than SC&A.
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

19 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

4.0 REFERENCES 

ICRP (International Commission on Radiological Protection) 1991. Recommendations of the 

International Commission on Radiological Protection, ICRP Publication 60, Pergamon Press, 

Oxford, England. 

OCAS-IG-001. 2007. External Dose Reconstruction Implementation Guideline, Rev. 3, 

National Institute for Occupational Safety and Health, Office of Compensation Analysis and 

Support, Cincinnati, Ohio. November 21, 2007. 

ORAUT-OTIB-0005. 2011. Technical Information Bulletin: Internal Dosimetry Organ, 

External Dosimetry Organ, and IREP Model Selection by ICD-9 Code, Rev. 04, Oak Ridge 

Associated Universities Team, Cincinnati, Ohio. April 18, 2011. 

ORAUT-OTIB-0006. 2011. Technical Information Bulletin: Dose Reconstruction from 

Occupationally Related Diagnostic X-Ray Procedures, Rev. 04, Oak Ridge Associated 

Universities Team, Cincinnati, Ohio. June 20, 2011. 

ORAUT-PROC-0006. 2006. External Dose Reconstruction, Rev. 01, Oak Ridge Associated 

Universities Team, Cincinnati, Ohio. June 5, 2006. 

ORAUT-TKBS-0048. 2013. Technical Basis Document Site Profile for the Brookhaven 

National Laboratory, Rev. 02, Oak Ridge Associated Universities Team, Cincinnati, Ohio. 

February 7, 2013. 

SC&A 2015a. Memo from Doug Farver, SC&A, to the Subcommittee on Dose Reconstruction, 

Subject: 20th DR Set – Blind Dose Reconstruction Reviews. SC&A, Inc., Vienna, Virginia. 

February 12, 2015.

SC&A 2015b. SC&A’s Blind Dose Reconstruction of Case #[Redact] from the Brookhaven 

National Laboratory, SCA-TR-BDR2015-CN039235, Rev. 0, SC&A, Inc., Vienna, Virginia. 

February 27, 2015.
Effective Date:

March 30, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-DRC2015-CN[Redact]

Page No.

20 of 20

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82.

ADDENDUM A: SC&A’S BLIND DOSE RECONSTRUCTION 

REPORT OF CASE #[REDACT] 
DRAFT 

REPORT TO THE ADVISORY BOARD 

ON RADIATION AND WORKER HEALTH

National Institute of Occupational Safety and Health 

BLIND DOSE RECONSTRUCTION OF CASE #[REDACT]

FROM THE BROOKHAVEN NATIONAL LABORATORY

Contract No. 211-2014-58081 

SCA-TR-BDR2015-CN[Redact]

Prepared by 

S. Cohen & Associates 

1608 Spring Hill Road, Suite 400 

Vienna, Virginia 22182 

February 27, 2015

Disclaimer

This document is made available in accordance with the unanimous desire of the Advisory Board on 

Radiation and Worker Health (ABRWH) to maintain all possible openness in its deliberations. However, 

the ABRWH and its contractor, SC&A, caution the reader that at the time of its release, this report is predecisional and has not been reviewed by the Board for factual accuracy or applicability within the 

requirements of 42 CFR 82. This implies that once reviewed by the ABRWH, the Board’s position may 

differ from the report’s conclusions. Thus, the reader should be cautioned that this report is for 

information only and that premature interpretations regarding its conclusions are unwarranted.
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

2 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

S. Cohen & Associates:

Technical Support for the Advisory Board on

Radiation & Worker Health Review of

NIOSH Dose Reconstruction Program

Document No. 

SCA-TR-BDR2015-CN[Redact]

Effective Date: 

Draft – February 27, 2015

Revision No.

0 (Draft)

BLIND DOSE RECONSTRUCTION 

OF CASE #[REDACT] FROM THE 

BROOKHAVEN NATIONAL LABORATORY

Page 2 of 26

Task Manager:

________________________ Date: _________

Douglas Farver, MS

Supersedes:

N/A

Project Manager:

________________________ Date: _________

John Stiver, CHP

Reviewers:

 Douglas Farver

 Rose Gogliotti

 Kathy Behling

 John Stiver

Record of Revisions

Revision 

Number Effective Date Description of Revision

0 (Draft) 02/27/2015 Initial issued.
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

3 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

TABLE OF CONTENTS 

Abbreviations and Acronyms ......................................................................................................... 4

1.0 Summary Background Information .................................................................................... 6

1.1 SC&A Blind DR Approach .................................................................................... 6

2.0 External Doses .................................................................................................................... 8

2.1 Recorded/CW Photon Doses ................................................................................... 9

2.2 Missed Photon Doses .............................................................................................. 9

2.3 Recorded Neutron Doses ...................................................................................... 10

2.4 Missed Neutron Doses .......................................................................................... 10

2.3 Occupational Medical Dose .................................................................................. 11

2.4 Onsite Ambient Dose ............................................................................................ 12

3.0 Internal Doses ................................................................................................................... 13

3.1 Internal Environmental Intake/Dose ..................................................................... 13

4.0 CATI Report and Radiological Incidents ......................................................................... 14

5.0 Summary Conclusions ...................................................................................................... 15

References ..................................................................................................................................... 16

Appendix A: IREP Input – Nasal Cavity ..................................................................................... 17
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

4 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

ABBREVIATIONS AND ACRONYMS 

Advisory Board Advisory Board on Radiation and Worker Health 

AP anterior-posterior

[Redact] [Redact]

BNL Brookhaven National Laboratory 

CADW Chronic Annual Dose Workbook 

CATI Computer-Assisted Telephone Interview 

CW coworker 

DCF dose conversion factor

DOE (U.S.) Department of Energy 

DOL (U.S.) Department of Labor 

DR dose reconstruction 

EE energy employee 

[Redact] [Redact]

HHS (U.S. Department of) Health and Human Services 

ICD International Classification of Diseases 

ICRP International Commission on Radiological Protection 

IMBA Integrated Modules of Bioassay Analysis 

IREP Interactive RadioEpidemiological Program 

keV kilo electron volt; 1,000 electron volts 

LAT lateral 

LOD limit of detection

MeV Million electron volts 

μCi/l microcuries per liter 

NIOSH National Institute for Occupational Safety and Health 

NM not monitored 

NTA Eastman Kodak Nuclear Track Film Type A 

ORAUT Oak Ridge Associated Universities Team 

PA posterior-anterior 

PFG photofluorography

POC probability of causation 

qt quarter 
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

5 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

rem Roentgen equivalent man 

SC&A S. Cohen and Associates (SC&A, Inc.) 

SEC Special Exposure Cohort 

SID Source to image distance 

TBD technical basis document 

TIB technical information bulletin

y year
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

6 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

1.0 SUMMARY BACKGROUND INFORMATION 

This report presents the results of an independent blind dose reconstruction (DR) performed by 

S. Cohen & Associates (SC&A, Inc.) for an energy employee (EE) who worked as a [redacted]

at the Brookhaven National Laboratory (BNL) from [redacted] through [redacted]. This was a 

partial DR, because not all internal doses could be assigned, as per the BNL Special Exposure 

Cohort (SEC). 

The EE was diagnosed with nasal cavity cancer (sinonasal melanomas of the [redacted] nasal 

cavity, ICD-9 Code 160.0) on [redacted].

According to ORAUT-TKBS-0048, page 12, the Secretary of the U.S. Department of Health and 

Human Services (HHS) has designated BNL employees as an addition to the SEC. Based on the

findings and recommendations of the National Institute for Occupational Safety and Health 

(NIOSH) and the Advisory Board on Radiation and Worker Health (Advisory Board), the 

Secretary of HHS has concurred with the finding that NIOSH does not have access to sufficient 

personnel or area monitoring data, or sufficient source or source term information, about BNL 

operations to bound potential internal exposures for the period from January 1, 1947, through 

December 31, 1993 (other than tritium after December 31, 1964). 

The EE was employed at BNL during the SEC period; however, since nasal cavity cancer is

considered a non-presumptive cancer, it was not covered under the SEC class; therefore, a DR 

was required. 

According to the Department of Labor (DOL) files and the Computer-Assisted Telephone 

Interview (CATI) report, the EE was a [redacted] and [redacted] at BNL. The EE was 

monitored for external photon exposure during most of the employment period at BNL. The EE 

first worked at the [redacted], and then the [redacted] during the remainder of the EE’s

employment at the BNL. 

1.1 SC&A BLIND DR APPROACH

SC&A reviewed all of the Department of Energy (DOE) records provided on behalf of this 

employee and the NIOSH procedures relevant to this case, which included the Technical Basis 

Document (TBD) for the BNL (ORAUT-TKBS-0048), ORAUT-OTIB-0005 for surrogate 

organs, OCAS-IG-001 for dose conversion factors (DCFs), and ORAUT-OTIB-0006 for 

occupational x-ray doses. Using the guidance provided in these documents, along with the 

employee’s dosimetry records, SC&A calculated reasonable, claimant-favorable annual organ 

doses for the nasal cavity. Table 1 provides a summary of the total doses assigned to the cancer 

site. Appendix A provides a list of SC&A’s assigned annual organ doses and also includes the 

Interactive RadioEpidemiological Program (IREP) input parameters, such as energy range, 

distribution type, and uncertainty for each year. 

SC&A determined the probability of causation (POC) for this case using the annual doses as 

input into the POC program. The total doses shown in Table 1 produced a POC of 51.05%. 
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

7 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Table 1. Summary of SC&A-Derived External/Internal Dose Estimates

Nasal cavity

IREP entry

Dose

(rem)

External Dose (Occupational)

 ▪ Recorded/CW Dose:

 30–250 keV Photons 1–35 5.664

 >250 keV Photons 36–70 11.469

 0.1–2 MeV Neutrons 71–77 1.802

 ▪ Missed Dose:

 30–250 keV Photons 78–114 1.550

 >250 keV Photons 115–151 3.138

 0.1–2 MeV Neutrons 152–188 11.917

 ▪ Occupational Medical Dose:

 30–250 keV Photons 189–213 0.157

Internal Dose, Environmental:

 <15 keV Electrons 214–262 0.161

 >15 keV Electrons 263–321 102.385

 <30 keV Photons 322–370 0.096

 >250 keV Photons 371–429 4.680

 Alpha 430–488 0.971

Total 143.990
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

8 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

2.0 EXTERNAL DOSES 

To perform this DR, SC&A analyzed the DOE files containing the quarterly totals of the badge 

readings (individual badge cycle data were not available), and one DOE file spreadsheet that 

provided a summary of doses received by this EE as of the 2nd quarter of [redacted].

SC&A used the DR parameters as recommended in ORAUT-TKBS-0048, which consisted of an 

energy range of 25% 30–250 keV photons, 75% >250 keV photons (Table 6-3, page 86); and 

100 keV–2 MeV neutrons with a neutron ICRP-60 (ICRP 1991) correction factor of 1.91 

(Table 6-5, page 87) and a Nuclear Track Film Type A (NTA) dosimeter fading correction factor 

of 1.81 (page 91); and a limit of detection (LOD) value of 0.030 rem for both photons and 

neutrons with a monthly badge exchange (Table 6-1, page 82). Exposure (as opposed to deep 

dose) conversion factors (DCFs) were used, as per ORAUT-TKBS-0048, page 90. The thyroid 

was used as the surrogate organ for the nasal cavity (ORAUT-OTIB-0005, page 15) because of it 

being in approximately the same physical location. In some cases, the Remainder organs DCF 

may be used; however, these organs are not located near the nasal cavity and would not be as 

applicable for external radiation to the nasal cavity as the thyroid. As recommended in OCASIG-001, for anterior-posterior (AP) geometry, a 30–250 keV photon DCF of 1.440 (page 61), a 

>250 keV photon DCF of 0.972 (page 61), and a 0.1–2 MeV neutron DCF of 1.086 (page 76) 

were used. 

The quarterly total recorded doses and zero values for photon, neutron, and shallow doses in the 

EE’s DOE files were very well organized and legible (shallow dose is not applicable to the nasal 

cavity). However, there was one discrepancy, in that one of the DOE file radiation reports listed 

a summary of dose received by this EE as of the 2nd quarter of [redacted] that indicated a 

Lifetime Total dose received while working at BNL that was 0.440 rem greater than the total of 

the doses received when summing up the quarterly values through the 2nd quarter of [redacted] 

(14.590 rem vs. 14.150 rem). There were 16 quarters when a notation of not monitored (NM) 

was entered into the EE’s records during the period [redacted]–[redacted]. Because the 

[redacted] did not operate until [redacted] (ORAUT-TKBS-0048, page 26), no additional doses 

were added for the two NM periods during [redacted]. The extra 0.440 rem of recorded 

exposure in the summary sheet could have occurred any time during the remaining 14 NM 

periods, and may not have been entered into the quarterly sums, but carried on the Lifetime Total 

dose. Therefore, to be claimant favorable, 0.220 rem was assigned to the first potentially missed 

monthly exchange in [redacted] and the remaining 0.220 rem to the second potentially missed 

monthly exchange in [redacted], which occurred during the 3rd quarter. The total 0.440 rem was 

not assigned during one monthly exchange, because that would exceed the 5 rem per year dose 

limit applicable at that time; i.e., 5.000 rem/y × (1/12 months/y) = 0.417 rem/month maximum. 

For all the other potentially missed monthly exchanges during the period [redacted]–[redacted],

which had the NM notation in the records, (as per ORAUT-TKBS-0048, page 82, 

recommendations for lost or destroyed badges) a monthly prorated coworker (CW) dose from the 

annual dose values, as recommended in ORAUT-TKBS-0048, Table 6-2, page 84, was applied 

as was appropriate for each year (this amounted to approximately 0.026 rem/month). 
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

9 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

2.1 RECORDED/CW PHOTON DOSES 

SC&A used the recorded photon dose values that were >LOD/2 of 0.015 rem, plus the extra 

0.440 rem, and CW doses for the NM periods to assign photon doses using the parameters 

previously described. 

Example of [redacted] recorded photon dose calculations – SC&A calculated the recorded 

[redacted] photon dose to the nasal cavity as follows:

Records show that for the four quarters of [redacted], the EE received a deep dose of 

0.160 rem + 0.410 rem + 0 + NM. This total of 0.570 rem recorded plus 0.079 rem CW

(0.317 rem/y × (1y/4 qt)) dose = 0.649 rem for [redacted]. The photon dose was assumed to 

be 25% 30–250 keV and 75% >250 keV. DCFs of 1.440 for 30–250 keV photons and 0.972 

for >250 keV photons were applied. 

30–250 keV photon dose = D.D. × DCF × Energy f. 

= 0.649 × 1.440 × 0.25 

= 0.234 rem 

 >250 keV photon dose = D.D. × DCF × Energy f. 

= 0.649 × 0.972 × 0.75 

= 0.473 rem 

SC&A’s calculated [redacted] 30–250 keV and >250 keV doses are shown in entries #10 and

#45, respectively, of Appendix A.

The recorded photon doses were entered into the IREP as a normal distribution with a 30% 

uncertainty (ORAUT-TKBS-0048, page 95, was the best guidance available). SC&A assigned a 

total of 17.133 rem recorded/CW dose in entries #1–#70 of the IREP Input table, as summarized 

in Table 1 and detailed in Appendix A. 

2.2 MISSED PHOTON DOSES

SC&A analyzed the number of physical zeros and potential zeros based on a monthly badge 

exchange cycle using the guidance in OCAS-IG-001, page 16, and a best-estimate reasonable 

approach to arrive at a total of 287 zeros, or <LOD/2 values, for photons. SC&A used the annual 

number of zeros, the LOD/2 value, the DR parameters as listed above, and the applicable DCF to 

determine the annual missed photon dose. 

Example of [redacted] missed photon dose calculations – SC&A calculated the missed 

[redacted] photon dose to the nasal cavity as follows:

Records show that for the four quarters of [redacted], the EE had received a deep dose of 

0.160 rem + 0.410 rem + 0 + NM. This results in a potential for seven zeros in [redacted]. 

The photon dose was assumed to be 25% 30–250 keV and 75% >250 keV. DCFs of 1.440 

for 30–250 keV photons and 0.972 for >250 keV photons were applied. 
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

10 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Missed Photon Dose (30–250 keV) = (# zeros × LOD/2) × DCF × Energy f. 

 = (7 × 0.015 rem) × 1.440 × 0.25 

 = 0.038 rem 

Missed Photon Dose (>250 keV) = (# zeros × LOD/2) × DCF × Energy f. 

 = (7 × 0.015 rem) × 0.972 × 0.75

 = 0.077 rem 

SC&A’s calculated 30–250 keV missed photon dose of 0.038 rem is shown in entry #88, and the 

>250 keV missed photon dose of 0.077 is shown in entry #125 of Appendix A. 

The missed photon doses were entered into IREP as a lognormal distribution with an uncertainty 

of 1.520. The total missed photon dose of 4.688 rem was assigned in entries #78–#151 of the 

IREP Input tables, as summarized in Table 1 and detailed in Appendix A. 

2.3 RECORDED NEUTRON DOSES 

SC&A used the recorded neutron dose values that were >LOD/2 of 0.015 rem to assign neutron 

doses using the DR parameters previously described. During periods when the EE was not 

monitored (NM in the records), additional neutron dose was not assigned because the POC 

exceeded 50% with the current dose assignments. 

Example of [redacted] recorded neutron dose calculations – SC&A calculated the recorded 

[redacted] neutron dose to the nasal cavity as follows:

Records show that for the four quarters of [redacted], the EE received a neutron dose of 

0.030 rem + 0.040 rem + 0.010 + NM. This resulted in a total of 0.070 rem, because the 

0.010 rem was less than the LOD/2 value of 0.015 rem. The neutron energy range was 

assumed to be 100% 0.1–2 MeV. A DCF of 1.086, a fading factor of 1.81, and an ICRP-60 

correction factor of 1.91 was used, as previously described.

0.1–2 MeV neutron dose = Neutron dose × Fading f. × ICRP f. × DCF × Energy f. 

 = 0.070 × 1.81 × 1.91 × 1.086 × 1.00 

 = 0.263 rem

This dose is shown in entry #74 of Appendix A. 

The recorded neutron doses were entered into the IREP as a normal distribution with an 

uncertainty of 30%. SC&A assigned a total of 1.802 rem in entries #71–#77 of the IREP Input 

table, as summarized in Table 1 and detailed in Appendix A. 

2.4 MISSED NEUTRON DOSES 

SC&A analyzed the number of physical zeros and potential zeros based on a monthly badge 

exchange cycle using the guidance in OCAS-IG-001, page 16, and a best-estimate reasonable 

approach to arrive at a total 383 zeros, or <LOD/2 values, for neutrons. SC&A used the annual 
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

11 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

number of zeros, the LOD/2 value, the DR parameters listed above, and the applicable DCF to 

determine the annual missed neutron dose. 

Example of [redacted] missed neutron dose calculations – SC&A calculated the missed 

[redacted] neutron dose to the nasal cavity as follows:

Records show that for the four quarters of [redacted], the EE had received a dose of 

0.030 rem + 0.040 rem + 0.010 + NM. This resulted in a potential total of 7 zeros 

(2 months/qt × 3 quarters plus one from the recorded 0.010 rem that was less than the LOD/2 

value of 0.015 rem). The neutron energy range was assumed to be 100% 0.1–2 MeV. A 

DCF of 1.086, and an ICRP-60 correction factor of 1.91 were used, as previously described. 

[Note that a fading factor of 1.81 was not applied to the missed neutron dose in this case,

because ORAUT-TKBS-0048, page 91, states, “The recorded neutron doses should be corrected 

by applying a multiplication factor of 1.81 (inverse of 55%);” it does not state to apply it to missed 

neutron dose.]

 0.1–2 MeV neutron dose = (#zeros × 0.015 rem) × ICRP f. × DCF × Energy f. 

 = (7 × 0.015 rem) × 1.91 × 1.086 × 1.00 

 = 0.218 rem 

This dose is shown in entry #162 of Appendix A. 

The missed neutron doses were entered into IREP as a lognormal distribution with an uncertainty 

of 1.520. The total missed neutron dose of 11.917 rem was assigned in entries #152–#188 of the

IREP Input table, as summarized in Table 1 and detailed in Appendix A. 

2.3 OCCUPATIONAL MEDICAL DOSE 

Records 

The DOE records show that the EE received one photofluorography (PFG) x-ray exam in 

[redacted] and 21 occupational medical x-ray exams (which were not for injuries, etc.) during 

the period [redacted]–[redacted]. Posterior-anterior (PA) views were assumed for all 22 exams, 

plus lateral (LAT) views for those taken after [redacted], as per ORAUT-TKBS-0048, 

Table 3-1, page 46. 

Surrogate Organ 

SC&A selected the occupational medical x-ray surrogate organ for the nasal cavity using the 

following recommendations: 

ORAUT-OTIB-0005, page 6, states: 

This TIB does not address the appropriate organ to use with medical X-ray 

procedures due to different potential exposure geometries of those procedures. 

The organs to be used for dose reconstruction from medical X-ray procedures can 

be found in ORAUT-OTIB-0006, Dose Reconstruction from Occupationally 
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

12 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Related Diagnostic X-Ray Procedures (ORAUT 2005), or the site-specific 

technical basis documents and site profiles. 

ORAUT-OTIB-0006, page 16 states:

The thyroid DCF is usually selected as the substitute to determine the dose to the 

eye/brain. However, one important exception to this generality is made for 

determining eye/brain dose from photofluorography (PFG) examinations of the 

chest. Because of the shorter SID used in PFG (40 in.) compared with 

radiographic chests (72 in.), the thyroid is most likely to be in the primary beam 

for PFG, while the eye/brain is most likely to be outside the primary beam of 

PFG. A better choice of a substitute DCF for the dose to the eye/brain for PFG is 

then one where the thyroid (as a substitute for the eye/brain) is just outside the 

primary beam. 

Therefore, SC&A used the eye/brain as the surrogate organ for the nasal cavity for the 

[redacted] PFG exam, and the thyroid for the PA and LAT views for the [redacted]–[redacted] 

exams. 

Using the appropriate organ dose values recommended in Table 3-3, page 51, of ORAUTTKBS-0048 as a function of the year the exam was performed, SC&A assigned a dose of 

0.073 rem for the PFG exam in entry #189 of the IREP Input table, a total dose of 0.061 rem for 

the PA views (entries #190–#210), and 0.024 rem for the LAT views (entries #211–#213), for a 

total occupational medical x-ray dose of 0.157 rem. These doses are summarized in Table 1 and 

detailed in Appendix A. The annual occupational medical dose values were entered into the 

IREP as a normal distribution with 30% uncertainty and a photon energy range of 30–250 keV. 

2.4 ONSITE AMBIENT DOSE 

As per ORAUT-TKBS-0048, Section 4.2.2, page 59, external ambient dose should not be 

applied when the EE is assigned recorded (and/or CW) dose. Therefore, no external ambient 

dose as assigned in this case, since the EE was assigned recorded and/or CW doses for all years 

of employment.
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

13 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

3.0 INTERNAL DOSES 

The DOE files for the EE provided little useful information concerning bioassay data. There was 

some indication that the EE was to have a plutonium urinalysis in [redacted], but no results are 

available. The EE may have had a whole-body count in [redacted], but no results are available. 

There is one bioassay for tritium performed in [redacted], with results recorded as <0.02 μCi/l. 

Therefore, considering this information and the BNL SEC concerning the lack of internal dose 

data, it is claimant favorable in this case to assign internal environmental dose. Coupled with the 

external dose assignments, this results in a POC of >50%; therefore, additional internal dose is 

not necessary in this case. 

3.1 INTERNAL ENVIRONMENTAL INTAKE/DOSE 

SC&A used the Chronic Annual Dose Workbook (CADW), which uses the inhalation values 

cited in Table 4-2 of ORAUT-TKBS-0048 for BNL to derive the environmental intakes and 

resulting doses to the nasal cavity [using ET1 as the Integrated Modules of Bioassay Analysis 

(IMBA) program organ and Other Respiratory as the IREP model organ, as per ORAUT-OTIB0005, page 15] for the years [redacted]–[redacted]. This resulted in a tritium dose of 

0.161 rem, a >15 keV electron dose of 102.385 rem, a <30 keV photon dose of 0.096 rem, a 

>250 keV photon dose of 4.680 rem, and an alpha dose of 0.971 rem, as listed in Table 1. The 

total internal dose assigned was 108.293 rem, as listed in entries #214–#488 of the IREP Input 

table and detailed in Appendix A. The annual dose values were entered into the IREP with a 

lognormal distribution and an uncertainty value of 3.000.
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

14 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

4.0 CATI REPORT AND RADIOLOGICAL INCIDENTS 

SC&A reviewed the EE’s DOE records and CATI report to determine if the EE was involved in 

any radiological incidents. SCA& did not find any documentation of radiological incidents that 

would impact the radiation doses assigned in this case. 
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

15 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

5.0 SUMMARY CONCLUSIONS 

This partial DR used best-estimate methods to obtain reasonable external and internal dose 

assignments. The derived total doses resulted in a POC >50%; therefore, the reconstruction of 

additional doses was not necessary. 

The total POC for the nasal cavity cancer was calculated using the IREP (v.5.7.1) and was 

determined to be 51.05%.
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

16 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

REFERENCES 

ICRP 1991. 1990 Recommendations of the International Commission on Radiological 

Protection, International Commission on Radiological Protection Publication 60, Pergamon 

Press, Oxford, England. 

OCAS-IG-001. 2007. External Dose Reconstruction Implementation Guideline, Rev. 3, 

National Institute for Occupational Safety and Health, Office of Compensation Analysis and 

Support, Cincinnati, Ohio. November 21, 2007. 

ORAUT-OTIB-0005. 2011. Technical Information Bulletin: Internal Dosimetry Organ, 

External Dosimetry Organ, and IREP Model Selection by ICD-9 Code, Rev. 04, Oak Ridge 

Associated Universities Team, Cincinnati, Ohio. April 18, 2011. 

ORAUT 2005. Technical Information Bulletin: Dose Reconstruction from Occupationally 

Related Diagnostic x-ray Procedures, ORAUT-OTIB-0006, Rev. 03, Oak Ridge Associated 

Universities Team, Cincinnati, Ohio. August 2, 2005. 

ORAUT-OTIB-0006. 2011. Technical Information Bulletin: Dose Reconstruction from 

Occupationally Related Diagnostic x-ray Procedures, Rev. 04, Oak Ridge Associated 

Universities Team, Cincinnati, Ohio. June 20, 2011. 

ORAUT-TKBS-0048. 2013. Technical Basis Document Site Profile for the Brookhaven 

National Laboratory, Rev. 02, Oak Ridge Associated Universities Team, Cincinnati, Ohio. 

February 7, 2013. 
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

17 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

APPENDIX A: IREP INPUT – NASAL CAVITY 

CLAIMANT CANCER DIAGNOSES

Primary

Cancer #1

Primary

Cancer #2

Primary

Cancer #3

Secondary 

Cancer #1

Secondary 

Cancer #2

Secondary

Cancer #3

Cancer Type

Sinonasal melanoma of the 

[redacted] nasal cavity N/A N/A N/A N/A N/A

Date of Diagnosis [redacted] N/A N/A N/A N/A N/A

EXPOSURE INFORMATION

Number of exposures

488

Exp. #

Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

1 [redacted] acute photons E=30–250 keV Normal 0.168 0.050 0.000

2 [redacted] acute photons E=30–250 keV Normal 0.056 0.017 0.000

3 [redacted] acute photons E=30–250 keV Normal 0.056 0.017 0.000

4 [redacted] acute photons E=30–250 keV Normal 0.128 0.038 0.000

5 [redacted] acute photons E=30–250 keV Normal 0.074 0.022 0.000

6 [redacted] acute photons E=30–250 keV Normal 0.092 0.028 0.000

7 [redacted] acute photons E=30–250 keV Normal 0.108 0.032 0.000

8 [redacted] acute photons E=30–250 keV Normal 0.036 0.011 0.000

9 [redacted] acute photons E=30–250 keV Normal 0.065 0.019 0.000

10 [redacted] acute photons E=30–250 keV Normal 0.234 0.070 0.000

11 [redacted] acute photons E=30–250 keV Normal 0.273 0.082 0.000

12 [redacted] acute photons E=30–250 keV Normal 0.036 0.011 0.000

13 [redacted] acute photons E=30–250 keV Normal 0.288 0.086 0.000

14 [redacted] acute photons E=30–250 keV Normal 0.504 0.151 0.000

15 [redacted] acute photons E=30–250 keV Normal 0.281 0.084 0.000

16 [redacted] acute photons E=30–250 keV Normal 0.410 0.123 0.000

17 [redacted] acute photons E=30–250 keV Normal 0.194 0.058 0.000

18 [redacted] acute photons E=30–250 keV Normal 0.050 0.015 0.000

19 [redacted] acute photons E=30–250 keV Normal 0.094 0.028 0.000

20 [redacted] acute photons E=30–250 keV Normal 0.076 0.023 0.000

21 [redacted] acute photons E=30–250 keV Normal 0.065 0.019 0.000

22 [redacted] acute photons E=30–250 keV Normal 0.086 0.026 0.000

23 [redacted] acute photons E=30–250 keV Normal 0.133 0.040 0.000

24 [redacted] acute photons E=30–250 keV Normal 0.277 0.083 0.000

25 [redacted] acute photons E=30–250 keV Normal 0.173 0.052 0.000

26 [redacted] acute photons E=30–250 keV Normal 0.198 0.059 0.000

27 [redacted] acute photons E=30–250 keV Normal 0.151 0.045 0.000

28 [redacted] acute photons E=30–250 keV Normal 0.212 0.064 0.000

29 [redacted] acute photons E=30–250 keV Normal 0.389 0.117 0.000

30 [redacted] acute photons E=30–250 keV Normal 0.097 0.029 0.000

31 [redacted] acute photons E=30–250 keV Normal 0.166 0.050 0.000

32 [redacted] acute photons E=30–250 keV Normal 0.158 0.048 0.000

33 [redacted] acute photons E=30–250 keV Normal 0.104 0.031 0.000

34 [redacted] acute photons E=30–250 keV Normal 0.130 0.039 0.000

35 [redacted] acute photons E=30–250 keV Normal 0.101 0.030 0.000

36 [redacted] acute photons E>250 keV Normal 0.340 0.102 0.000

37 [redacted] acute photons E>250 keV Normal 0.114 0.034 0.000

38 [redacted] acute photons E>250 keV Normal 0.114 0.034 0.000

39 [redacted] acute photons E>250 keV Normal 0.260 0.078 0.000

40 [redacted] acute photons E>250 keV Normal 0.150 0.045 0.000

41 [redacted] acute photons E>250 keV Normal 0.187 0.056 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

18 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

42 [redacted] acute photons E>250 keV Normal 0.219 0.066 0.000

43 [redacted] acute photons E>250 keV Normal 0.073 0.022 0.000

44 [redacted] acute photons E>250 keV Normal 0.131 0.039 0.000

45 [redacted] acute photons E>250 keV Normal 0.473 0.142 0.000

46 [redacted] acute photons E>250 keV Normal 0.553 0.166 0.000

47 [redacted] acute photons E>250 keV Normal 0.073 0.022 0.000

48 [redacted] acute photons E>250 keV Normal 0.583 0.175 0.000

49 [redacted] acute photons E>250 keV Normal 1.021 0.306 0.000

50 [redacted] acute photons E>250 keV Normal 0.569 0.171 0.000

51 [redacted] acute photons E>250 keV Normal 0.831 0.249 0.000

52 [redacted] acute photons E>250 keV Normal 0.394 0.118 0.000

53 [redacted] acute photons E>250 keV Normal 0.102 0.031 0.000

54 [redacted] acute photons E>250 keV Normal 0.190 0.057 0.000

55 [redacted] acute photons E>250 keV Normal 0.153 0.046 0.000

56 [redacted] acute photons E>250 keV Normal 0.131 0.039 0.000

57 [redacted] acute photons E>250 keV Normal 0.175 0.052 0.000

58 [redacted] acute photons E>250 keV Normal 0.270 0.081 0.000

59 [redacted] acute photons E>250 keV Normal 0.561 0.168 0.000

60 [redacted] acute photons E>250 keV Normal 0.350 0.105 0.000

61 [redacted] acute photons E>250 keV Normal 0.401 0.120 0.000

62 [redacted] acute photons E>250 keV Normal 0.306 0.092 0.000

63 [redacted] acute photons E>250 keV Normal 0.430 0.129 0.000

64 [redacted] acute photons E>250 keV Normal 0.787 0.236 0.000

65 [redacted] acute photons E>250 keV Normal 0.197 0.059 0.000

66 [redacted] acute photons E>250 keV Normal 0.335 0.101 0.000

67 [redacted] acute photons E>250 keV Normal 0.321 0.096 0.000

68 [redacted] acute photons E>250 keV Normal 0.211 0.063 0.000

69 [redacted] acute photons E>250 keV Normal 0.262 0.079 0.000

70 [redacted] acute photons E>250 keV Normal 0.204 0.061 0.000

71 [redacted] chronic neutrons E=100 keV–2 MeV Normal 0.150 0.045 0.000

72 [redacted] chronic neutrons E=100 keV–2 MeV Normal 0.713 0.214 0.000

73 [redacted] chronic neutrons E=100 keV–2 MeV Normal 0.375 0.113 0.000

74 [redacted] chronic neutrons E=100 keV–2 MeV Normal 0.263 0.079 0.000

75 [redacted] chronic neutrons E=100 keV–2 MeV Normal 0.150 0.045 0.000

76 [redacted] chronic neutrons E=100 keV–2 MeV Normal 0.075 0.023 0.000

77 [redacted] chronic neutrons E=100 keV–2 MeV Normal 0.075 0.023 0.000

78 [redacted] acute photons E=30–250 keV Lognormal 0.027 1.520 0.000

79 [redacted] acute photons E=30–250 keV Lognormal 0.049 1.520 0.000

80 [redacted] acute photons E=30–250 keV Lognormal 0.032 1.520 0.000

81 [redacted] acute photons E=30–250 keV Lognormal 0.032 1.520 0.000

82 [redacted] acute photons E=30–250 keV Lognormal 0.022 1.520 0.000

83 [redacted] acute photons E=30–250 keV Lognormal 0.027 1.520 0.000

84 [redacted] acute photons E=30–250 keV Lognormal 0.027 1.520 0.000

85 [redacted] acute photons E=30–250 keV Lognormal 0.054 1.520 0.000

86 [redacted] acute photons E=30–250 keV Lognormal 0.059 1.520 0.000

87 [redacted] acute photons E=30–250 keV Lognormal 0.049 1.520 0.000

88 [redacted] acute photons E=30–250 keV Lognormal 0.038 1.520 0.000

89 [redacted] acute photons E=30–250 keV Lognormal 0.022 1.520 0.000

90 [redacted] acute photons E=30–250 keV Lognormal 0.059 1.520 0.000

91 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

92 [redacted] acute photons E=30–250 keV Lognormal 0.032 1.520 0.000

93 [redacted] acute photons E=30–250 keV Lognormal 0.038 1.520 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

19 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter

3

94 [redacted] acute photons E=30–250 keV Lognormal 0.032 1.520 0.000

95 [redacted] acute photons E=30–250 keV Lognormal 0.049 1.520 0.000

96 [redacted] acute photons E=30–250 keV Lognormal 0.054 1.520 0.000

97 [redacted] acute photons E=30–250 keV Lognormal 0.049 1.520 0.000

98 [redacted] acute photons E=30–250 keV Lognormal 0.065 1.520 0.000

99 [redacted] acute photons E=30–250 keV Lognormal 0.054 1.520 0.000

100 [redacted] acute photons E=30–250 keV Lognormal 0.054 1.520 0.000

101 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

102 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

103 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

104 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

105 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

106 [redacted] acute photons E=30–250 keV Lognormal 0.054 1.520 0.000

107 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

108 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

109 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

110 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

111 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

112 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

113 [redacted] acute photons E=30–250 keV Lognormal 0.043 1.520 0.000

114 [redacted] acute photons E=30–250 keV Lognormal 0.011 1.520 0.000

115 [redacted] acute photons E>250 keV Lognormal 0.055 1.520 0.000

116 [redacted] acute photons E>250 keV Lognormal 0.098 1.520 0.000

117 [redacted] acute photons E>250 keV Lognormal 0.066 1.520 0.000

118 [redacted] acute photons E>250 keV Lognormal 0.066 1.520 0.000

119 [redacted] acute photons E>250 keV Lognormal 0.044 1.520 0.000

120 [redacted] acute photons E>250 keV Lognormal 0.055 1.520 0.000

121 [redacted] acute photons E>250 keV Lognormal 0.055 1.520 0.000

122 [redacted] acute photons E>250 keV Lognormal 0.109 1.520 0.000

123 [redacted] acute photons E>250 keV Lognormal 0.120 1.520 0.000

124 [redacted] acute photons E>250 keV Lognormal 0.098 1.520 0.000

125 [redacted] acute photons E>250 keV Lognormal 0.077 1.520 0.000

126 [redacted] acute photons E>250 keV Lognormal 0.044 1.520 0.000

127 [redacted] acute photons E>250 keV Lognormal 0.120 1.520 0.000

128 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

129 [redacted] acute photons E>250 keV Lognormal 0.066 1.520 0.000

130 [redacted] acute photons E>250 keV Lognormal 0.077 1.520 0.000

131 [redacted] acute photons E>250 keV Lognormal 0.066 1.520 0.000

132 [redacted] acute photons E>250 keV Lognormal 0.098 1.520 0.000

133 [redacted] acute photons E>250 keV Lognormal 0.109 1.520 0.000

134 [redacted] acute photons E>250 keV Lognormal 0.098 1.520 0.000

135 [redacted] acute photons E>250 keV Lognormal 0.131 1.520 0.000

136 [redacted] acute photons E>250 keV Lognormal 0.109 1.520 0.000

137 [redacted] acute photons E>250 keV Lognormal 0.109 1.520 0.000

138 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

139 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

140 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

141 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

142 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

143 [redacted] acute photons E>250 keV Lognormal 0.109 1.520 0.000

144 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

145 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

20 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

146 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

147 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

148 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

149 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

150 [redacted] acute photons E>250 keV Lognormal 0.087 1.520 0.000

151 [redacted] acute photons E>250 keV Lognormal 0.022 1.520 0.000

152 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.156 1.520 0.000

153 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.280 1.520 0.000

154 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.156 1.520 0.000

155 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.187 1.520 0.000

156 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.187 1.520 0.000

157 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.124 1.520 0.000

158 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.156 1.520 0.000

159 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

160 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

161 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

162 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.218 1.520 0.000

163 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.187 1.520 0.000

164 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

165 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

166 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

167 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.311 1.520 0.000

168 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

169 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

170 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

171 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.342 1.520 0.000

172 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

173 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

174 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.342 1.520 0.000

175 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

176 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

177 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

178 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

179 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

180 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

181 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

182 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

183 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

184 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

185 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

186 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

187 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.373 1.520 0.000

188 [redacted] chronic neutrons E=100 keV–2 MeV Lognormal 0.311 1.520 0.000

189 [redacted] acute photons E=30–250 keV Normal 7.250E-02 0.022 0.000

190 [redacted] acute photons E=30–250 keV Normal 7.26E-03 0.002 0.000

191 [redacted] acute photons E=30–250 keV Normal 7.26E-03 0.002 0.000

192 [redacted] acute photons E=30–250 keV Normal 7.26E-03 0.002 0.000

193 [redacted] acute photons E=30–250 keV Normal 7.26E-03 0.002 0.000

194 [redacted] acute photons E=30–250 keV Normal 7.26E-03 0.002 0.000

195 [redacted] acute photons E=30–250 keV Normal 7.26E-03 0.002 0.000

196 [redacted] acute photons E=30–250 keV Normal 7.26E-03 0.002 0.000

197 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

21 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

198 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

199 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

200 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

201 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

202 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

203 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

204 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

205 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

206 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

207 [redacted] acute photons E=30–250 keV Normal 5.06E-04 0.000 0.000

208 [redacted] acute photons E=30–250 keV Normal 1.38E-03 0.000 0.000

209 [redacted] acute photons E=30–250 keV Normal 1.38E-03 0.000 0.000

210 [redacted] acute photons E=30–250 keV Normal 1.38E-03 0.000 0.000

211 [redacted] acute photons E=30–250 keV Normal 7.98E-03 0.002 0.000

212 [redacted] acute photons E=30–250 keV Normal 7.98E-03 0.002 0.000

213 [redacted] acute photons E=30–250 keV Normal 7.98E-03 0.002 0.000

214 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

215 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

216 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

217 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

218 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

219 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

220 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

221 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

222 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

223 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

224 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

225 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

226 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

227 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

228 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

229 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

230 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

231 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

232 [redacted] chronic electrons E<15 keV Lognormal 0.003 3.000 0.000

233 [redacted] chronic electrons E<15 keV Lognormal 0.003 3.000 0.000

234 [redacted] chronic electrons E<15 keV Lognormal 0.007 3.000 0.000

235 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

236 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

237 [redacted] chronic electrons E<15 keV Lognormal 0.006 3.000 0.000

238 [redacted] chronic electrons E<15 keV Lognormal 0.008 3.000 0.000

239 [redacted] chronic electrons E<15 keV Lognormal 0.006 3.000 0.000

240 [redacted] chronic electrons E<15 keV Lognormal 0.007 3.000 0.000

241 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

242 [redacted] chronic electrons E<15 keV Lognormal 0.001 3.000 0.000

243 [redacted] chronic electrons E<15 keV Lognormal 0.002 3.000 0.000

244 [redacted] chronic electrons E<15 keV Lognormal 0.004 3.000 0.000

245 [redacted] chronic electrons E<15 keV Lognormal 0.023 3.000 0.000

246 [redacted] chronic electrons E<15 keV Lognormal 0.037 3.000 0.000

247 [redacted] chronic electrons E<15 keV Lognormal 0.035 3.000 0.000

248 [redacted] chronic electrons E<15 keV Lognormal 0.014 3.000 0.000

249 [redacted] chronic electrons E<15 keV Lognormal 0.002 3.000 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

22 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

250 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

251 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

252 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

253 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

254 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

255 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

256 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

257 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

258 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

259 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

260 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

261 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

262 [redacted] chronic electrons E<15 keV Lognormal 0.000 3.000 0.000

263 [redacted] chronic electrons E>15 keV Lognormal 1.775 3.000 0.000

264 [redacted] chronic electrons E>15 keV Lognormal 1.780 3.000 0.000

265 [redacted] chronic electrons E>15 keV Lognormal 1.780 3.000 0.000

266 [redacted] chronic electrons E>15 keV Lognormal 1.781 3.000 0.000

267 [redacted] chronic electrons E>15 keV Lognormal 1.781 3.000 0.000

268 [redacted] chronic electrons E>15 keV Lognormal 1.781 3.000 0.000

269 [redacted] chronic electrons E>15 keV Lognormal 1.781 3.000 0.000

270 [redacted] chronic electrons E>15 keV Lognormal 1.780 3.000 0.000

271 [redacted] chronic electrons E>15 keV Lognormal 1.807 3.000 0.000

272 [redacted] chronic electrons E>15 keV Lognormal 1.807 3.000 0.000

273 [redacted] chronic electrons E>15 keV Lognormal 1.807 3.000 0.000

274 [redacted] chronic electrons E>15 keV Lognormal 1.807 3.000 0.000

275 [redacted] chronic electrons E>15 keV Lognormal 1.811 3.000 0.000

276 [redacted] chronic electrons E>15 keV Lognormal 1.923 3.000 0.000

277 [redacted] chronic electrons E>15 keV Lognormal 1.752 3.000 0.000

278 [redacted] chronic electrons E>15 keV Lognormal 1.757 3.000 0.000

279 [redacted] chronic electrons E>15 keV Lognormal 1.759 3.000 0.000

280 [redacted] chronic electrons E>15 keV Lognormal 1.736 3.000 0.000

281 [redacted] chronic electrons E>15 keV Lognormal 37.293 3.000 0.000

282 [redacted] chronic electrons E>15 keV Lognormal 1.739 3.000 0.000

283 [redacted] chronic electrons E>15 keV Lognormal 1.705 3.000 0.000

284 [redacted] chronic electrons E>15 keV Lognormal 1.704 3.000 0.000

285 [redacted] chronic electrons E>15 keV Lognormal 1.703 3.000 0.000

286 [redacted] chronic electrons E>15 keV Lognormal 1.703 3.000 0.000

287 [redacted] chronic electrons E>15 keV Lognormal 1.704 3.000 0.000

288 [redacted] chronic electrons E>15 keV Lognormal 1.704 3.000 0.000

289 [redacted] chronic electrons E>15 keV Lognormal 2.119 3.000 0.000

290 [redacted] chronic electrons E>15 keV Lognormal 2.119 3.000 0.000

291 [redacted] chronic electrons E>15 keV Lognormal 2.119 3.000 0.000

292 [redacted] chronic electrons E>15 keV Lognormal 2.120 3.000 0.000

293 [redacted] chronic electrons E>15 keV Lognormal 2.119 3.000 0.000

294 [redacted] chronic electrons E>15 keV Lognormal 3.040 3.000 0.000

295 [redacted] chronic electrons E>15 keV Lognormal 2.022 3.000 0.000

296 [redacted] chronic electrons E>15 keV Lognormal 2.018 3.000 0.000

297 [redacted] chronic electrons E>15 keV Lognormal 2.486 3.000 0.000

298 [redacted] chronic electrons E>15 keV Lognormal 0.762 3.000 0.000

299 [redacted] chronic electrons E>15 keV Lognormal 0.001 3.000 0.000

300 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

301 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

23 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

302 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

303 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

304 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

305 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

306 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

307 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

308 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

309 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

310 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

311 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

312 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

313 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

314 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

315 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

316 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

317 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

318 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

319 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

320 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

321 [redacted] chronic electrons E>15 keV Lognormal 0.000 3.000 0.000

322 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

323 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

324 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

325 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

326 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

327 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

328 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

329 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

330 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

331 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

332 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

333 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

334 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

335 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

336 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

337 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

338 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

339 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

340 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

341 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

342 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

343 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

344 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

345 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

346 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

347 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

348 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

349 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

350 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

351 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

352 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

353 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

24 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

354 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

355 [redacted] chronic photons E<30 keV Lognormal 0.004 3.000 0.000

356 [redacted] chronic photons E<30 keV Lognormal 0.003 3.000 0.000

357 [redacted] chronic photons E<30 keV Lognormal 0.002 3.000 0.000

358 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

359 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

360 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

361 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

362 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

363 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

364 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

365 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

366 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

367 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

368 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

369 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

370 [redacted] chronic photons E<30 keV Lognormal 0.000 3.000 0.000

371 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

372 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

373 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

374 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

375 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

376 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

377 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

378 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

379 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

380 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

381 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

382 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

383 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

384 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

385 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

386 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

387 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

388 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

389 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

390 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

391 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

392 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

393 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

394 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

395 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

396 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

397 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

398 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

399 [redacted] chronic photons E>250 keV Lognormal 0.109 3.000 0.000

400 [redacted] chronic photons E>250 keV Lognormal 0.228 3.000 0.000

401 [redacted] chronic photons E>250 keV Lognormal 0.232 3.000 0.000

402 [redacted] chronic photons E>250 keV Lognormal 0.233 3.000 0.000

403 [redacted] chronic photons E>250 keV Lognormal 0.233 3.000 0.000

404 [redacted] chronic photons E>250 keV Lognormal 0.233 3.000 0.000

405 [redacted] chronic photons E>250 keV Lognormal 0.233 3.000 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

25 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

406 [redacted] chronic photons E>250 keV Lognormal 0.114 3.000 0.000

407 [redacted] chronic photons E>250 keV Lognormal 0.001 3.000 0.000

408 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

409 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

410 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

411 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

412 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

413 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

414 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

415 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

416 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

417 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

418 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

419 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

420 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

421 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

422 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

423 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

424 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

425 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

426 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

427 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

428 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

429 [redacted] chronic photons E>250 keV Lognormal 0.000 3.000 0.000

430 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

431 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

432 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

433 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

434 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

435 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

436 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

437 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

438 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

439 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

440 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

441 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

442 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

443 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

444 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

445 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

446 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

447 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

448 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

449 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

450 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

451 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

452 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

453 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

454 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

455 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

456 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

457 [redacted] chronic alpha Lognormal 0.027 3.000 0.000
Effective Date:

February 27, 2015

Revision No.

0 (Draft)

Document No. 

SCA-TR-BDR2015-CN[Redact]

Page No.

26 of 26

NOTICE: This report has been reviewed for Privacy Act information and has been cleared for distribution. 

However, this report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker 

Health for factual accuracy or applicability within the requirements of 42 CFR 82. 

Appendix A: IREP Input – Nasal Cavity (continued) 

Exp. # Exposure 

Year

Exposure 

Rate Radiation Type

Dose 

Distribution 

Type

Parameter 

1

Parameter 

2

Parameter 

3

458 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

459 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

460 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

461 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

462 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

463 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

464 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

465 [redacted] chronic alpha Lognormal 0.027 3.000 0.000

466 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

467 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

468 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

469 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

470 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

471 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

472 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

473 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

474 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

475 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

476 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

477 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

478 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

479 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

480 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

481 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

482 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

483 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

484 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

485 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

486 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

487 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

488 [redacted] chronic alpha Lognormal 0.000 3.000 0.000

OTHER ADVANCED FEATURES

Sample Size Random Seed

2000 99

User Defined Uncertainty Distribution

Dose Distribution Type Parameter 1 Parameter 2 Parameter 3

Lognormal 1.000 1.000 0.000

SKIN CANCER INPUTS Not used for

Ethnic Origin cancer selected:

[redacted] Other respiratory